Tariffs move into pharma

The White House just pushed tariffs into one of the hardest places to swap suppliers: patented medicines. A proclamation dated April 2 says some imported patented pharmaceuticals and their ingredients can face tariffs as high as 100%, using national security law instead of the usual trade case. (whitehouse.gov) This is not about cheap copycat drugs. The order targets medicines with valid, unexpired United States patents, which are the branded products listed in the Food and Drug Administration’s Orange Book or Purple Book, while generic drugs and biosimilars are excluded for now. (whitehouse.gov) (realeconomy.rsmus.com) The administration’s argument is that the United States invented a lot of these drugs but does not make enough of them at home. The proclamation says that as of 2025 about 53% of patented pharmaceutical products sold domestically were produced outside the country, and only 15% of patented active pharmaceutical ingredient volume was made domestically for the United States market. (whitehouse.gov) A tariff works like a toll booth at the border. That toll is easier to dodge when a company can switch to another supplier, but a patented cancer drug or autoimmune treatment is usually tied to a specific approved factory, a specific formula, and a specific regulatory file. (whitehouse.gov) (realeconomy.rsmus.com) That is why this move is different from tariffs on shirts or furniture. In pharmaceuticals, changing where a drug is made can mean new validation work, new inspections, and new filings with the Food and Drug Administration, so companies cannot reroute supply chains as quickly as a retailer changing toy factories. (realeconomy.rsmus.com) The tariff is also not a flat 100% for everyone. RSM says the European Union, Japan, South Korea, and Switzerland negotiated 15% rates, the United Kingdom finalized 0% for UK-made medicines as of April 2, and some large drugmakers already cut separate deals tied to United States manufacturing or “most favored nation” pricing. (realeconomy.rsmus.com) There are carveouts too. RSM says products for rare diseases, cell and gene therapies, and animal health products can be exempt if they meet specific trade and security conditions or urgent health-need tests. (realeconomy.rsmus.com) The rollout is staggered, which tells you companies are expected to scramble before the clock runs out. RSM says goods from companies listed in Annex III become subject to the tariffs on July 31, 2026, while most other affected companies face the tariffs on September 29, 2026, unless they negotiate lower rates. (realeconomy.rsmus.com) That timing creates a familiar playbook: import more before the deadline, then park inventory where duty can be delayed. RSM specifically points to front-loading shipments, building safety stock, and using foreign trade zones or bonded warehouses to defer tariff payments. (realeconomy.rsmus.com) You can already see the earnings effect of this broader tariff wave outside pharma. Tecnoglass said this week that a new 10% United States tariff on finished aluminum window imports would cut its 2026 adjusted earnings before interest, taxes, depreciation, and amortization guidance to $225 million to $245 million, a $50 million hit versus the midpoint of its prior outlook. (markets.businessinsider.com) (financecolombia.com) Pharmaceutical companies are walking into the same math with less room to maneuver. When the product is patented, medically necessary, and tied to a regulated production line, a border tax stops looking like a negotiating tactic and starts looking like a direct cost that someone in the chain has to absorb. (whitehouse.gov) (realeconomy.rsmus.com)